FURAN-FUSED RING-SUBSTITUTED GLUTARIMIDE COMPOUND Russian patent published in 2025 - IPC C07D405/14 C07D493/04 A61K31/445 A61K31/4523 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, which are modulators of targeted ubiquitination and degradation of the androgen receptor (AR) and can be used for treating prostate cancer. In formula (II), PTM is selected from the following fragments; L₁ selected from -(CH₂)_n- and each CH₂ optionally substituted with R₁; R₁ selected from C_3-7cycloalkyl, 6-membered heterocycloalkyl, -NR_a-, -CR_bR_c-, -CH₂CH₂O-, -NHC(=O)- and -C(=O)NH-; R_a selected from H and C_1-3alkyl; each of R_b and R_c is independently selected from H, D and F; E 1 is selected from a single bond and O; ring A is absent; or ring A is selected from phenyl and 5-member heteroaryl; n is selected from 1, 2, 3, 4, 5 and 6; 6-member heterocycloalkyl and 5-member heteroaryl contain 1 or 2 heteroatoms independently selected from -O- and N, respectively; provided that a number of compounds are excluded.

EFFECT: invention also relates to specific compounds and to the use of the disclosed compounds in the manufacture of a medicinal agent for treating prostate cancer.

10 cl, 2 dwg, 15 tbl, 17 ex

PTM:

and